AFTVac / Cell-Medicine - LARVOL DELTA

Association between autologous formalin-fixed tumor vaccine (AFTV) therapy, molecular pathological markers, and survival outcomes in glioblastoma. (PubMed, Brain Tumor Pathol) - "These findings establish AFTV as a promising treatment option for GBM and highlight the importance of molecular profiling in treatment selection. Future studies should explore combining AFTV with immune checkpoint inhibitors to enhance efficacy in PD-L1-positive cases."

IO biomarker • Journal • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • TP53

Thirty-Five-Year Follow-Up Real-World Data Revealed the Efficacy of Autologous Formalin-Fixed Tumor Vaccine on Metastatic Breast Cancer-A Target Trial Emulation. (PubMed, Clin Breast Cancer) - "The present real-world data suggest that Optimum AFTV Set therapy may be a useful option for treatment following the detection of distant metastasis after breast cancer surgery."

Journal • Real-world evidence • Breast Cancer • Oncology • Solid Tumor

PIK3R2 immunostaining status predicts prognosis in patients with newly diagnosed glioblastoma treated with an autologous tumor vaccine. (PubMed, J Neurooncol) - "Negative immunostaining for PIK3R2 as well as negative p53 revealed an increased survival in patients receiving AFTV therapy for GBM. In patients receiving AFTV, these immunostaining results may serve as a predictor of treatment efficacy and overall survival."

IO biomarker • Journal • Anaplastic Astrocytoma • Astrocytoma • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • PD-1 • PIK3R2 • TP53

A randomized, placebo-controlled phase III trial of an autologous, formalin-fixed tumor vaccine for newly diagnosed glioblastoma: trial protocol. (PubMed, Jpn J Clin Oncol) - "Given the growing interest in immunotherapy (IMT), we developed an autologous formalin-fixed tumor vaccine (AFTV) manufactured from the patient's own glioblastoma multiforme (GBM) tissue in paraffin-embedded blocks made from the resected tumor and a double-blind, randomized phase IIB trial of AFTV with temozolomide in newly diagnosed GBM was conducted. The 3-year progression-free survival (PFS) rate for patients with gross total resection (GTR) on imaging tended toward improvement: 81% in the AFTV group versus 46% in the placebo group (P = .067). Based on these IIB results, the feasibility of conducting a phase III trial was confirmed for IIB-eligible patients with total resection. We here plan to conduct the world's first double-blind, randomized, placebo-controlled phase III trial using Cellm-001 to demonstrate autologous tumor immunostimulant efficacy. This IMT, in combination with sub-analyses (GTR, P53 status, CD8 score, and other factors) to be..."

Journal • P3 data • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • CD8 • TP53

Efficacy and Safety of Vaccines After Conventional Treatments for Survival of Gliomas: A Systematic Review and Meta-Analysis. (PubMed, Oncol Rev) - "In addition, AFTV, peptide, and dendritic cell-based vaccines are among the most efficient vaccines for gliomas. Personalized vaccines also showed considerable efficacy for glioma treatments."

Retrospective data • Review • Brain Cancer • CNS Tumor • Fatigue • Glioma • Oncology • Pain • Solid Tumor

B Long-Term Clinical Results Of 493 Cases Of Newly Diagnosed Glioblastoma And Survival Benefit By Combination With Pdt And Aftv, Aiming To Establish New Standard Treatment (EANO 2023) - "CONCLUSION The treatment results for glioblastoma have improved over the years. The combination of maximal tumor removal using iMRI, PDT and AFTV may aim for a 5-year survival rate of 50%."

Clinical • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

P53-negative status and gross total resection as predictive factors for autologous tumor vaccine treatment in newly diagnosed glioblastoma patients. (PubMed, Neurooncol Adv) - "A p53-negative status in IHC and GTR were the predictive factors for AFTV treatment in newly diagnosed GBM patients. Microenvironment-targeted treatment and pretreatment blood cell status may be key factors to enhance therapy effects."

Biomarker • Journal • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor

TRANSITION OF LONG-TERM TREATMENT RESULTS OF 493 CASES OF NEWLY DIAGNOSED GLIOBLASTOMA AND SURVIVAL BENEFIT BY COMBINATION WITH PDT AND AFTV - AIMING TO ESTABLISH NEW STANDARD TREATMENT (SNO 2022) - "CONCLUSION The treatment results for glioblastoma have improved over the years. The combination of maximal tumor removal using iMRI, PDT and AFTV may aim for a 5-year survival rate of 50%."

Clinical • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Maximum resection and immunotherapy improve glioblastoma patient survival: a retrospective single-institution prognostic analysis. (PubMed, BMC Neurol) - "In the multivariate analysis, GTR, proton therapy, and a combination of immunotherapies, including autologous formalin-fixed tumor vaccine, were the significant prognostic factors...In conclusion, GTR, proton therapy, and immunotherapy were good prognostic factors in single-center GBM cases. Tumor vaccine therapy for GTR cases achieved a notably high median survival time and long-term survival ratio, indicating its usefulness in GTR cases."

Journal • Retrospective data • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor • MRI

Eradication of breast carcinoma with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with radiation and chemotherapy (AACR 2018) - "...We then treated her with the aromatase inhibitor, anastrozole...We treated her again with second course of AFTV and palliative radiation therapy (36Gy/12fractions/19days) together with letrozole, bisphosphonate, additional 2 shots of nivolmab (40mg/48kg body) in October and November 2015...Alteration of her blood CEA level suggests that the combined treatments eradicated the metastatic breast carcinoma. In conclusion, the present case suggests that AFTV in combination with palliative X-ray irradiation and adjuvant aromatase inhibitors eradicates skeletal metastasis of breast carcinoma with enhancement of a specific anti-tumor immune reactivity."

HER2 Breast Cancer • Hormone Receptor Breast Cancer

"via @NYTimes, Wow! Pay attention ⁦@UFT⁩ ⁦@AFTunion⁩ ⁦@rweingarten⁩ ⁦@DistCouncil37⁩ ⁦@1199SEIU⁩ Good on ⁦@NEJM⁩ #AFTVote ⁦@CityAndStateNY⁩ ⁦@politico⁩ https://t.co/affS5Swpog" (@mosalty)

"This is true! #AFTVOUT" (@GoonerScots)

"Lol 99% of your tweets are about AFTV" (@kindlysmbd)

"Check out our newest collaboration @MayoAnesthesia @rossrenew The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlight... https://t.co/AFtvXzReUU" (@avfDO)